HUM Chart

1 Month

	Date	Diff
	2025-04-01	+0.05 %
The article discusses an investigation by Bragar Eagel & Squire into potential claims against Humana Inc. (HUM) following a class action lawsuit alleging the company misled investors about earnings pressures due to increased healthcare utilization, despite Humana's stock seeing a slight increase of 0.05% recently, likely due to market factors such as optimism about future performance or broader market trends.
	2025-03-31	+0.01 %
Humana (HUM) stock saw a slight increase of 0.01% as it has experienced mixed institutional investment activity, with significant changes in holdings from various hedge funds, indicating investor interest and confidence. The stock's rise may be attributed to positive elements such as the company's recent quarterly earnings report, which surpassed analyst expectations, and the announcement of a dividend payment, suggesting financial stability and shareholder return.
	2025-03-28	-2.15 %
The article discusses the decline of Humana (HUM) stock, which fell by 2.15% following ongoing criticisms of for-profit health insurance companies and growing momentum for Medicare for All, as illustrated by health care whistleblower Wendell Potter's insights into the industry's conflicting incentives that prioritize profits over patient care.
	2025-03-24	+2.09 %
Humana Inc. (HUM) stock rose by 2.09% likely due to several institutional investors increasing their holdings in the company, recent positive analyst ratings adjustments, and a strong quarterly earnings report that beat estimates, suggesting improving investor confidence. Humana Inc. (HUM) stock increased by 2.09% due to positive investor sentiment stemming from recent buy and sell movements among institutional investors, price upgrades by analysts, and the company beating earnings estimates for the latest quarter.
	2025-03-19	-0.9 %
Humana (HUM) stock decreased by 0.9% following a downgrade from a buy rating to a hold rating by StockNews.com and a series of lowered price targets from several investment firms, indicating a cautious outlook among analysts.
	2025-03-17	+4.56 %
Humana (HUM) stock increased by 4.56% due to a notable uptick in institutional investment, with several firms increasing their holdings, suggesting positive sentiment among investors regarding the company's future performance and stability.
	2025-03-13	+1.05 %
Humana Inc. (HUM) stock increased by 1.05% due to a mix of institutional trading activity, including significant purchases by large investors and technical factors, along with positive recent earnings results that exceeded analyst expectations.
	2025-03-11	-0.42 %
Humana (HUM) stock declined by 0.42% attributed to significant changes in institutional ownership, including Keybank National Association reducing its stake by 36.3%, and insider selling, which may have raised concerns among investors.
	2025-02-27	+2.5 %
Humana (HUM) stock increased by 2.5% following an upgrade from analysts at StockNews.com from a "hold" to a "buy" rating, along with other analysts raising their price targets for the stock. Humana Inc. (HUM) stock increased by 2.5% following substantial investments from institutional investors, indicating strong confidence in the company's future performance and recent earnings results surpassing expectations. The rise in Humana's stock price can be attributed to the bullish sentiment among institutional investors, with several increasing their stakes significantly, as well as positive quarterly earnings that exceeded analyst predictions, which suggests strong operational performance and investor confidence.
	2025-02-19	+3.22 %
Humana Inc. (HUM) stock rose 3.22% due to increased institutional investment activity, with several hedge funds significantly boosting their stakes in the company, indicating positive market sentiment.
	2025-02-18	+1.34 %
Humana Inc. (NYSE:HUM) stock rose by 1.34% following a significant increase in institutional investment, notably a 36.5% stake boost by Vontobel Holding Ltd. and positive adjustments in analysts' price targets for the company's shares. The rise in HUM stock can be attributed to increased institutional investments which indicate growing confidence in the company, alongside favorable reviews and price target upgrades from several research firms.
	2025-02-14	+0.38 %
Humana Inc. (NYSE:HUM) saw a 0.38% increase in its stock price despite analysts lowering earnings estimates for the company, likely due to mixed analyst ratings and positive movements from institutional investors increasing their stakes in the company. Humana (NYSE:HUM) stock rose by 0.38% following a mixed bag of analyst ratings, with price targets adjusted by several brokerages, most notably a decrease from Morgan Stanley, which maintained an "equal weight" rating while still indicating potential upside from its previous close. The stock's increase is likely attributed to positive quarterly earnings that exceeded analysts' expectations, along with general optimism from recent upgrades and interest from institutional investors.
	2025-02-13	-2.75 %
Humana (HUM) stock declined by 2.75% likely due to rising concerns about increasing medical costs associated with its Medicare Advantage plans, which have prompted the company to cut lower-profit membership and adjust plan offerings, similar to strategies undertaken by competitors like CVS and other insurance firms facing similar challenges. Humana (HUM) stock dropped 2.75% primarily due to mixed reactions following its recent earnings report, where it reported a narrower-than-expected loss but overall investor sentiment may be impacted by adjustments in price targets and insider selling activity.
	2025-02-12	+1.05 %
Humana (HUM) stock rose 1.05% following CVS Health's strong fourth-quarter earnings report, which highlighted issues such as rising medical costs and a management change that may have reassured investors about potential improvements in the insurance sector, which includes players like Humana.
	2025-02-11	-3.55 %
Humana (HUM) stock fell 3.55% due to overall market volatility driven by rising Treasury yields, mixed earnings reports, and concerns related to President Trump's tariff plans, which could impact the broader economy and healthcare sector. Humana (HUM) stock fell 3.6% due to concerns over its profit forecast for 2025, which did not meet investor expectations, despite reporting a smaller-than-expected loss.
	2025-02-07	-1.88 %
Humana Inc. (HUM) stock fell by 1.88% after Trust Point Inc. reduced its holdings in the company by 10.2%, reflecting broader trends in institutional investment activity that may have influenced investor sentiment.
	2025-02-04	+0.86 %
Humana Inc. (HUM) stock rose by 0.86% following a generally positive sentiment from analysts, with numerous upgrades and target price increases, indicating confidence in the company's performance and potential growth in the near future.
	2025-01-30	+0.91 %
Humana Inc. (HUM) stock rose 0.91% likely due to positive earnings results that exceeded consensus estimates and recent institutional investment activity indicating confidence in the company's performance. Humana Inc. (HUM) stock rose by 0.91% likely due to strong quarterly earnings that exceeded expectations, as well as substantial investments and changes in holdings from institutional investors, indicating positive market sentiment.
	2025-01-29	-2.93 %
The article discusses the increasing importance of AI expertise across industries and how companies must cultivate mission-driven cultures, offer innovative projects, and provide competitive benefits to attract top AI talent. Humana's (HUM) stock may have declined by -2.93% due to its struggles in showcasing a strong commitment to AI advancements and attracting top-tier AI professionals amid a competitive market for talent.
	2025-01-24	+0.28 %
Humana Inc. (NYSE:HUM) stock rose by 0.28% as several institutional investors have increased their holdings in the company, alongside positive earnings results that exceeded analyst expectations, which likely boosted investor confidence. Humana Inc. (NYSE:HUM) stock saw a 0.28% increase due to significant institutional investment activity, with Assenagon Asset Management S.A. and several other funds boosting their holdings in the company, suggesting growing confidence among investors in Humana's financial performance and future prospects. Humana Inc. (HUM) stock rose by 0.28% as analysts at Cantor Fitzgerald projected earnings of $16.17 per share for FY2025, exceeding the current consensus estimate, contributing to positive investor sentiment. Humana (HUM) stock increased by 0.28% due to significant buying interest from institutional investors, including a notable 16.6% stake increase by Merit Financial Group LLC, indicating growing confidence in the company's performance.
	2025-01-22	+0.09 %
Hormel Foods (HRL) stock saw a slight increase of 0.09% due to a mix of analyst price target adjustments and continued interest from institutional investors. The stock rises likely because Barclays raised its price target and other analysts have expressed stable/hold sentiments, indicating a stable outlook amidst mixed earnings results and strong insider buying activity.
	2025-01-16	-1.32 %
Humana (HUM) stock declined by 1.32% following a significant drop in UnitedHealth Group’s shares due to persistent high medical costs and revenue that fell short of expectations, which negatively impacted investor confidence across the health insurance sector. Humana Inc. (NYSE:HUM) stock decreased by 1.32% due to a series of negative analyst ratings and price target reductions, which may have influenced investor sentiment and market performance.
	2025-01-15	-1.11 %
Humana Inc. (NYSE:HUM) stock experienced a decline of -1.11% as various institutional investors increased their positions, indicating mixed market sentiment and potential concerns from analysts regarding the company's future performance. The decrease in Humana's stock price could be attributed to lowered price targets from several research firms, signaling a more cautious outlook for the insurer's valuation. Humana Inc. (HUM) stock declined by 1.11% amid fluctuating institutional investments and analyst downgrades, which have recently lowered price targets for the company from previous estimates.
	2025-01-14	-1.65 %
Humana (HUM) stock fell by 1.65%, likely due to growing public outrage against the pharmaceutical industry over high drug prices and unethical practices, fueled by ongoing scrutiny and criticism of healthcare companies, as well as potential regulatory changes aimed at reducing drug costs. Humana (HUM) stock fell by 1.65% amid a proposal from the Centers for Medicare and Medicaid Services to increase Medicare Advantage payments by an average of 4.3%, which could indicate heightened competition or uncertainties in the sector.
	2025-01-13	+6.81 %
Humana (HUM) stock rose by nearly 7% amid a positive performance from the broader S&P 500, despite remaining in a downtrend; the increase could be attributed to overall market movements and the company's resilience compared to other stocks in a challenging market. Humana (HUM) stock rose 6.81% as Medicare proposed larger-than-expected payments for insurance companies in 2026, boosting investor confidence in Humana's prospects.
	2025-01-10	+0.34 %
Humana (HUM) stock rose 0.34% after a proposal indicated that Medicare Advantage plan payments are set to increase by 4.3% in 2026, potentially enhancing revenue for the company amid concerns of previous inadequate rates.
	2025-01-08	+0.34 %
The article discusses various health policy issues and developments, including record enrollment in the Affordable Care Act and recent legislative initiatives, but it does not specifically address Humana (HUM) stock or the reasons for its increase of 0.34%. It is speculative, but Humana's stock may have risen due to positive market reactions to ongoing discussions around healthcare policy, health insurance enrollment trends, or company-specific developments not detailed in the article.
	2025-01-06	+0.69 %
Humana (HUM) stock increased by 0.69% following a target price increase by Truist Financial from $260.00 to $290.00, suggesting potential upside and indicating positive outlook among analysts despite a mix of ratings from other firms.
	2024-12-31	-0.22 %
Humana (HUM) stock experienced a slight decline of 0.22% due to concerns over insurers, such as Blue Cross Blue Shield, denying coverage for critical mental health treatments, which can lead to severe consequences for patients and potentially result in financial liabilities for the companies involved.
	2024-12-20	+4.8 %
Humana Inc. (HUM) stock rose by 3.1% after Morgan Stanley increased its price target for the stock from $288.00 to $301.00, while maintaining an equal weight rating, reflecting renewed investor confidence following positive quarterly earnings.
	2024-12-19	-1.7 %
Humana (HUM) stock declined by 1.7% despite an increase in the target price from Morgan Stanley, as analysts maintain mostly neutral ratings on the stock, indicating a lack of strong upward momentum along with market volatility. Humana (HUM) stock fell by 1.7% due to concerns over rising administrative costs, increased regulatory scrutiny on Medicare Advantage program practices, and potential vulnerabilities following security issues impacting major health insurers like UnitedHealth Group, which affect the overall managed care industry. Humana (HUM) stock declined by 1.7% following a settlement regarding a whistleblower lawsuit that uncovered systemic fraud in the Medicare Advantage program, raising concerns about financial impacts resulting from tighter regulations and increased scrutiny of health insurers' billing practices.
	2024-12-17	-10.2 %
Humana (HUM) stock has fallen 19% recently, contributing to a broader decline in health insurance stocks following the killing of UnitedHealth Group's CEO, which has led to investor concerns about the healthcare system and its impact on public sentiment towards large insurers.
	2024-12-16	-4.98 %
Humana Inc. (NYSE:HUM) stock fell by 4.98% following a series of downgrades and reduced price targets from multiple equity research analysts who advised a “hold” rating on the stock amid concerns about its future performance.
	2024-12-13	+0.49 %
Humana (HUM) stock rose by 0.49% amid concerns over threats directed at health insurance company employees following the assassination of UnitedHealthcare CEO Brian Thompson, highlighting broader issues in the healthcare system that have been acknowledged by UnitedHealth Group CEO Andrew Witty. The increase may be attributed to the market's focus on necessary industry changes and potential regulatory response, which could benefit health insurers like Humana in the long term.
	2024-12-12	-1.95 %
Humana (HUM) stock is down due to the overall decline in health insurance stocks following the murder of UnitedHealthcare CEO Brian Thompson, which has sparked public scrutiny over the insurance industry and the potential for legislative changes that could impact company operations.
	2024-12-09	+1.6 %
Humana (HUM) stock rose 1.6% amid a broader market decline in health insurance stocks following the murder of UnitedHealthcare CEO Brian Thompson, with renewed scrutiny on the industry prompting significant selloffs in rival firms, reflecting public outcry against for-profit insurance practices. The article provides a fictional dialogue discussing a conspiracy theory around the murder of UnitedHealthcare CEO Brian Thompson, suggesting corporate motivations behind the crime, while noting that Humana (HUM) stock increased by 1.6%. Humana's stock may have gone up due to market speculation or investor sentiment following the news of UHC's CEO murder, potentially placing Humana in a favorable position within the healthcare sector amid increased scrutiny on competitors.
	2024-12-06	-0.47 %
Humana (HUM) stock declined by 0.47% following the high-profile shooting of UnitedHealth Group executive Brian Thompson, which has reignited public anger over the healthcare insurance industry's failure to adequately cover medical expenses and address consumer grievances, exacerbating distrust in the sector. Humana (HUM) stock fell by 0.47%, likely influenced by analysts' downgrades and decreased target prices, as well as overall market performance amid mixed investor sentiment. Humana (HUM) stock declined by 0.47% following heightened public anger towards the health insurance industry, intensified by the recent shooting of a high-ranking UnitedHealth executive, which exposed widespread dissatisfaction about insurance practices and claims denials. Humana (HUM) stock fell by 0.47% following heightened safety concerns in the healthcare industry after the murder of UnitedHealth Group's CEO, which led to precautionary measures by healthcare companies to protect their executives. Humana (HUM) stock declined by 0.47% amidst a broader selloff in health insurance stocks, primarily due to heightened industry scrutiny and public sentiment following the recent murder of UnitedHealthcare's CEO, which led to concerns about potential coverage decisions and regulatory pressures affecting industry profits.
	2024-12-04	-1.05 %
Humana (HUM) stock was down 1.05% due to investor concerns regarding leadership changes, specifically the appointment of a new CFO, which often indicates strategic shifts and uncertainties within a company. Humana (HUM) stock fell by -1.05% amid concerns regarding regulatory scrutiny over Mehmet Oz's endorsements of herbal products, which could reflect negatively on the management of Medicare and related industries, especially as the Biden administration implements stricter rules that affect healthcare reimbursement rates.
	2024-11-29	-0.1 %
Humana (HUM) stock dipped by 0.1% following a significant 78.6% reduction in institutional investor Brown Brothers Harriman & Co.'s stake, alongside various adjustments by other hedge funds, which may indicate waning investor confidence in the company's outlook.
	2024-11-25	+2.04 %
Humana Inc. (HUM) stock rose by 2.04% following positive quarterly earnings results that exceeded analysts' expectations, alongside increased institutional investment interest and favorable price target adjustments from several brokerages.
	2024-11-22	+0.81 %
Humana Inc. (NYSE:HUM) stock rose 0.81% due to strong quarterly earnings that exceeded analyst expectations, as well as significant institutional investments enhancing confidence in the company's performance.
	2024-11-20	+5.83 %
The article discusses how Humana (HUM) stock rose by 5.83% following the appointment of Dr. Mehmet Oz, who has a significant financial interest in Medicare Advantage, as the head of the Centers for Medicare and Medicaid Services, indicating potential favorable policies for companies in this sector. Humana's stock likely increased due to market optimism regarding potential expansion and investment in Medicare Advantage plans, which the new CMS leadership might support.
	2024-11-19	+2.37 %
Humana Inc. (HUM) stock rose by 2.37% following strong quarterly earnings that exceeded analysts' expectations, despite a downward adjustment for Q4 2024 earnings estimates by Zacks Research. Humana Inc. (NYSE:HUM) stock rose by 2.37% likely due to positive earnings performance that exceeded estimates, increased interest from institutional investors, and recent analyst upgrades to price targets, despite receiving a consensus “Hold” recommendation.
	2024-11-18	-1.57 %
Humana Inc. (NYSE:HUM) stock fell by 1.57% due to a significant 15.9% increase in short interest, downgrades from several analysts with reduced target prices, and broader negative sentiment reflected in trading activities. Humana Inc. (HUM) stock decreased by 1.57% following a significant reduction in holdings by Sigma Planning Corp, which cut its position by 65.7% during the third quarter, reflecting a broader trend of mixed institutional investor activity.
	2024-11-15	-2.64 %
The article discusses Humana (HUM) stock, which experienced a decline of 2.64%. The reason for the stock's drop is not specified in the provided text.
	2024-11-13	+3.34 %
Humana (HUM) stock rose by 3.34% following positive institutional investment activities, including increased stakes from firms like Crossmark Global Holdings and a strong quarterly earnings report that surpassed analysts' expectations. Humana Inc. (NYSE:HUM) stock rose by 3.34% following the acquisition of new stakes by institutional investors, strong quarterly earnings that exceeded analysts' expectations, and positive dividend announcements. Humana Inc. (HUM) stock rose by 3.34% partly due to increased institutional investments, with Assetmark Inc. and other firms significantly expanding their holdings in the company, suggesting growing confidence in its performance following a strong earnings report that exceeded analysts' expectations.
	2024-11-12	-0.84 %
Humana (HUM) stock declined by 2% due to Cigna not pursuing a merger, which fueled uncertainty around potential consolidation in the insurance sector amid broader market movements associated with President Trump's reelection.
	2024-11-11	-1.97 %
Humana (HUM) stock fell by 1.97% following Cigna Group's announcement that it is not exploring a merger with Humana, which may have dampened investor sentiment about Humana's growth prospects. Humana (HUM) stock fell by 1.97% after Cigna Group announced that it is not pursuing a merger with Humana, which decreased investor confidence in Humana's potential growth or strategic opportunities. Humana (HUM) stock fell by 1.97% following Cigna's confirmation that it is not seeking a merger with Humana, amid ongoing investor speculation about potential consolidation in the healthcare sector. Humana Inc. (HUM) stock declined 1.97% following a series of downgrades from analysts and a general consensus rating of "Hold," reflecting cautious sentiment among investors amid recent market activity. The primary reason for the stock's decline is the negative impact of several analyst downgrades and reductions in price targets, leading to increased caution among investors. Humana (HUM) stock fell by 1.97% following Cigna Group's announcement that it is not pursuing a merger with Humana, amid growing concerns regarding higher medical expenses in the Medicare Advantage market and Cigna's strategic shift away from Medicare.
	2024-11-06	+10.71 %
Humana Inc. (NYSE:HUM) stock surged 10.71% after reporting better-than-expected quarterly earnings and revenue, with earnings per share of $4.16, exceeding estimates of $3.48, which likely boosted investor confidence despite several recent downgrades from analysts. Humana Inc. (NYSE:HUM) saw a 10.71% increase in its stock price, likely driven by positive quarterly earnings results that exceeded analyst expectations and a notable increase in institutional investor interest.
	2024-11-05	+1.98 %
Humana Inc. (HUM) stock rose by 1.98% following an increase in FY2024 earnings per share estimates by Cantor Fitzgerald, which positively influenced investor sentiment despite mixed ratings from other analysts. The increase in Humana's stock is attributed to analysts raising their EPS estimates based on the company’s better-than-expected quarterly earnings results, which surpassed analysts’ forecasts. Humana (HUM) stock was up 1.98% last night primarily due to its strong quarterly earnings report, which exceeded analysts’ expectations, along with various institutional investments and the announcement of a quarterly dividend.
	2024-11-01	+1.12 %
Humana (HUM) stock rose 1.12% amid investor optimism surrounding the upcoming presidential election, with analysts expecting that a potential win for Trump could lead to favorable corporate tax cuts and decreased regulations, which historically boosts equity markets. Humana Inc. (NYSE:HUM) stock rose 1.12% following the company's robust quarterly earnings report, which exceeded analysts' expectations for earnings per share and revenue, along with the announcement of a quarterly dividend. The increase in Humana's stock price can be attributed to the company's strong financial performance that beat consensus estimates, indicating operational strength and potentially improving investor sentiment.
	2024-10-31	-3.19 %
Humana Inc. (NYSE:HUM) stock declined by 3.19% after Nisa Investment Advisors LLC reduced its holdings in the company by 6.2%, indicating a potential lack of investor confidence or a response to broader market trends.
	2024-10-30	+3.32 %
Humana (HUM) stock rose by 3.32% amid broader market declines primarily due to positive investor sentiment, possibly driven by favorable recent earnings reports or strategic developments in the healthcare sector. Humana (HUM) stock rose by 3.32% following the announcement of earnings and revenues that exceeded estimates, along with an upgrade to its full-year guidance, indicating strong financial performance. Humana Inc. (HUM) experienced a 3.32% increase in stock price following a notable rise in short interest, which surged by 41.6% in October, indicating a potential shift in market sentiment or investor expectations. Humana (HUM) stock rose by 3.32% due to positive market sentiment amidst an overall decline in other benchmark equity indices, reflecting a potential investor interest in healthcare stocks as a stable sector during market fluctuations. Humana (NYSE:HUM) stock rose 4.9% due to positive market sentiment and factors potentially influencing its performance, though specific reasons for the increase were not detailed in the article.
	2024-10-29	-1.27 %
Humana Inc. (HUM) stock fell by 1.27% as the State of Alaska Department of Revenue reduced its stake in the company by 18.1%, signaling potential concerns among institutional investors and impacting market sentiment. Humana Inc. (NYSE:HUM) stock fell 1.27% as some hedge funds reduced their holdings, and research firms downgraded the stock's ratings and target prices, indicating a shift in investor sentiment and outlook for the company. Humana Inc. (HUM) stock fell by 1.27% following the State of Alaska Department of Revenue's decision to reduce its stake in the company by 18.1% in the third quarter.
	2024-10-28	+0.14 %
Forsta AP Fonden increased its stake in Humana Inc. (HUM) by 13.3% in the third quarter, contributing to a slight 0.14% rise in the stock's value. The increase in institutional investment may indicate growing confidence in the company's prospects, thereby driving the stock price up.
	2024-10-24	-0.03 %
Humana (HUM) stock decreased by -0.03% due to significant declines in the Medicare Advantage STAR ratings, which affect plan quality perceptions and revenue, leading to concerns about future financial performance and member satisfaction with their plans. Humana (HUM) stock experienced a slight decline of 0.03% due to Creative Planning reducing its holdings by 8.6%, selling 2,273 shares in the third quarter. Humana (HUM) stock decreased by 0.03% as several analysts downgraded their ratings and target price estimates, contributing to uncertainty among investors despite the company's strong quarterly earnings report.
	2024-10-23	-1.4 %
Humana (HUM) stock dropped by 1.4% ahead of its upcoming quarterly earnings report, with analysts adjusting price targets downwards, indicating potential market concerns over its future performance.
	2024-10-22	+0.67 %
Humana Inc. (HUM) stock rose by 0.67% following increased institutional investment in the company, with hedge funds and institutional investors lifting their stakes during the 3rd quarter, indicating positive sentiment toward the stock's potential. Humana Inc. (NYSE:HUM) stock rose by 0.67%, with a consensus recommendation of "Hold" from 25 research firms, indicating a stable outlook despite mixed ratings from analysts. The increase in stock price may be attributed to overall market conditions or investor sentiment around the company's performance, despite no strong buy signals from analysts. The article discusses a recent increase in Humana (HUM) stock, which rose 0.67%, potentially influenced by positive developments in the market, including related news about Spirit Airlines and broader trends in the healthcare sector.
	2024-10-21	-2.46 %
Humana (HUM) stock fell by 1.5% amid reports that Cigna had resumed merger talks with the health insurer, contributing to a broader decline in the market due to rising Treasury yields and investor caution ahead of upcoming earnings reports. Humana (HUM) stock fell by 2.46% last night, despite Mandatum Life Insurance Co Ltd increasing its holdings in the company by 115.4% in the third quarter, reflecting potential market concerns or broader industry issues affecting stock performance. Humana (HUM) stock fell by 2.46% amidst ongoing challenges such as a decline in Medicare plan enrollments, rising medical care costs, and reduced government reimbursements, despite earlier speculation of a potential merger with Cigna (CI). Humana (HUM) stock fell 2.46% amid concerns that the potential resumption of merger negotiations with rival Cigna could create regulatory challenges and uncertainty in the market. Humana (HUM) stock fell 2.46% as renewed merger talks with Cigna (CI) surfaced amid Humana's struggles with Medicare Advantage cost overruns and a significant loss in star ratings, impacting its valuation and future revenue potential.
	2024-10-18	+0.3 %
Humana (HUM) stock rose 0.3% amid CVS Health's struggles with rising Medicare-related costs and leadership changes, which could indicate investor optimism for Humana's better performance in the health insurance market as CVS faces challenges. Humana (HUM) stock rose by 0.3% potentially in response to CVS Health's leadership changes and ongoing struggles, which may shift investor focus and increase attention on Humana's performance amidst the healthcare industry's challenges. The article discusses the resignation of CVS Health CEO Karen Lynch amid the company's struggles and disappointing financial forecasts, leading to a significant drop in CVS Health's stock, while Humana (HUM) stock increased by 0.3% as it may have benefited from CVS's challenges in the health insurance sector, potentially attracting investors to Humana as a stronger alternative.
	2024-10-17	+4.21 %
Humana Inc. (HUM) stock rose 4.21% following Swedbank AB's increase in its stake in the company by 3.0%, reflecting investor confidence and potential positive outlook for the insurer.
	2024-10-15	-3.74 %
Humana (HUM) stock dropped by 3.74% after several research firms downgraded their ratings and significantly lowered price targets, indicating a more cautious outlook for the company's financial performance. Humana (HUM) stock fell by 3.74% following a significant reduction in its price target by Truist Financial, which cut it from $400.00 to $260.00, indicating a hold rating amidst multiple recent downgrades from various analysts.
	2024-10-14	+3.69 %
Humana Inc. (HUM) stock rose by 3.69% as institutional investors increased their holdings in the company, reflecting growing confidence in its performance, despite recent downgrades from several equities analysts.
	2024-10-11	+2.64 %
Humana (HUM) stock rose 2.64% as Private Advisory Group LLC significantly increased its stake in the company by 54.0% during the 3rd quarter, indicating strong investor confidence. Humana (HUM) stock rose by 2.64% following the initiation of coverage by KeyCorp with a "sector weight" rating, alongside positive sentiment from other brokerages. Humana (HUM) stock rose by 2.64% despite analysts at Truist Financial dropping their target price from $400.00 to $260.00, likely due to investor sentiment responding positively to other factors influencing the company or market conditions.
	2024-10-10	+2.44 %
Humana Inc. (HUM) stock increased by 2.44% amid Tobam's reported 19.4% reduction in holdings, suggesting market confidence despite the decrease in institutional ownership. Humana (HUM) stock increased by 2.44% despite Barclays lowering its target price from $364.00 to $250.00, likely due to other positive market influences or investor sentiment outweighing the downgrade.
	2024-10-09	+0.93 %
Humana (HUM) stock rose by 0.93% following the acquisition of shares by Future Financial Wealth Management LLC and ongoing interest from other institutional investors, which indicates positive market sentiment despite some recent downgrades and target price cuts from research analysts. Humana (HUM) stock increased by 0.93% after investment analysts at Stephens reaffirmed their "equal weight" rating and set a price target of $250.00 for the insurance provider's shares. The article notes that Humana (NYSE:HUM) stock was up 0.93% after analysts at Stephens reiterated their equal weight rating for the company, maintaining a target price of $250.00, which likely contributed to investor confidence and the stock's increase.
	2024-10-08	+2.92 %
Humana (HUM) stock rose 2.92% after Bernstein analysts upgraded the stock, stating that its recent decline made it an attractive investment. Humana (HUM) stock rose by 2.92% despite a price target reduction from $400.00 to $265.00 by Royal Bank of Canada, which maintains an "outperform" rating, indicating investor confidence in the company's performance despite the adjustment. Humana's stock (NYSE:HUM) rose by 2.92% following an upgrade from Sanford C. Bernstein, which changed its rating from "market perform" to "outperform" and set a target price of $308.00. Humana Inc. (NYSE:HUM) experienced a 2.92% increase in stock price due to unusually high options trading activity, with investors purchasing 12,200 call options, a 32% increase over average volume, indicating bullish sentiment.
	2024-10-07	-1.56 %
Humana (HUM) stock fell by 1.56% after the Centers for Medicare and Medicaid Services assigned low grades to many of its health plans, which could significantly impact future enrollment. Humana (HUM) stock declined by 1.56% following Renaissance Technologies LLC's significant reduction of its stake in the company by 98.3% during the second quarter, as reported in their filing with the SEC. Humana (HUM) stock fell by 1.56% last night, likely due to broader market volatility or negative investor sentiment affecting healthcare stocks, particularly as investors react to recent market shifts and regulatory uncertainties. The article discusses a recent decline in Humana (HUM) stock, which was down 1.56%, amid concerns following disappointing earnings results and decreased guidance related to increased utilization of Medicare Advantage plans and weaknesses in its health services segment. Humana (HUM) stock declined by 1.56% following a downgrade from Jefferies, which cited negative impacts from the company's recent Medicare ratings, particularly a drop in star ratings that affects bonus payments, compounded by ongoing concerns over increased medical costs and regulatory challenges.
	2024-10-04	-0.72 %
Humana (HUM) stock has declined by 0.72%, potentially due to concerns around increasing medical costs associated with Medicare Advantage plans and lower star ratings impacting future profitability, similar to the challenges faced by CVS Health, which is also grappling with high medical expenses in its insurance unit. Humana Inc. (HUM) stock experienced a decrease of 0.72% after a brief 2% increase following three days of declines, which may be linked to the performance of its bonds indicating investor sentiment. Humana (HUM) stock fell 0.72% after analysts at UBS Group downgraded their price target for the stock from $380 to $250, maintaining a "neutral" rating, which likely raised concerns among investors about the company's future performance. Humana (HUM) stock recently fell by 0.72%, marking a significant drop of 23% over the week, attributed primarily to unfavorable changes in Medicare Star Ratings that have affected investor confidence. Humana (HUM) stock fell by 0.72% following a downgrade by Bank of America and a drop in Medicare Star Ratings, which negatively impacted the performance outlook for their key Medicare plan.
	2024-10-03	-1.91 %
Humana Inc. (HUM) stock fell by 1.91% following an investigation by Johnson Fistel, LLP into potential securities law violations related to the company’s recent drop in Medicare Advantage quality ratings, heightening concerns over its future revenue prospects and leading to an overall decline in share value. Humana (HUM) stock declined by 11.8% as part of a broader market downturn influenced by geopolitical tensions in the Middle East, disruptions in global supply chains due to a US dock workers' strike, and concerns over new regulations impacting future trading, which collectively increased market volatility and investor caution. Humana Inc. (HUM) stock fell by 1.91% as part of a broader market decline, influenced by escalating geopolitical tensions and new SEBI regulations aimed at reducing retail participation in speculative trading, which negatively impacted market sentiment. Humana (HUM) stock fell by 1.91% amid a broader market decline influenced by geopolitical tensions in the Middle East and concerns surrounding new regulatory changes by SEBI that may impact trading volumes and increased volatility. The decline in Humana stock was exacerbated by a significant drop in its sector and overall market sentiment. Humana (HUM) stock dropped by 1.91% amid rising geopolitical tensions in the Middle East, which along with mixed global market cues and regulatory changes in India, contributed to overall market uncertainty and investor caution.

1
500 / page